{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:21:39Z","timestamp":1772706099027,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejca.2018.07.125","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T05:59:05Z","timestamp":1534744745000},"page":"49-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rituximab in the treatment of pembrolizumab-induced myasthenia gravis"],"prefix":"10.1016","volume":"102","author":[{"given":"S.M.","family":"Crusz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Radunovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Newey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Shamash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.07.125_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.07.125_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2018.07.125_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2018.07.125_bib4","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2018.07.125_bib5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.07.125_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.ejca.2018.07.125_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/nyas.13562","article-title":"Rituximab in myasthenia gravis: a \u201cto be or not to be\u201d inhibitor of T cell function","volume":"1413","author":"Marino","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.ejca.2018.07.125_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust Prescr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918310943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918310943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T08:20:02Z","timestamp":1537172402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918310943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":8,"alternative-id":["S0959804918310943"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.125","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in the treatment of pembrolizumab-induced myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}